Blar i St. Olavs hospital på tidsskrift "Annals of Oncology"

Viser treff 1-3 av 3

    • Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial 

      Rakaee, Mehrdad; Andersen, S.; Giannikou, K.; Paulsen, Erna-Elise; Kilvær, Thomas Karsten; Rasmussen Busund, Lill-Tove; Berg, Thomas; Richardsen, Elin; Lombardi, Ana Paola; Adib, E.; Pedersen, Mona Irene; Tafavvoghi, Masoud; Wahl, Sissel Gyrid Freim; Petersen, R.H.; Bondgaard, A.L.; Yde, C.W.; Baudet, C.; Licht, P.; Lund-Iversen, Marius; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helland, Åslaug; Pøhl, M.; Kwiatkowski, D.J.; Dønnem, Tom (Peer reviewed; Journal article, 2023)
      Background We aim to implement an immune cell score model in routine clinical practice for resected non-small-cell lung cancer (NSCLC) patients (NCT03299478 ). Molecular and genomic features associated with immune ...

    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2020)
      Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ...

    • Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial 

      Nilsson, K.; Klevebro, F.; Sunde, B.; Rouvelas, I.; Lindblad, M.; Szabo, E.; Halldestam, I.; Smedh, U.; Wallner, B.; Johansson, J.; Johnsen, Gjermund; Aahlin, Eirik Kjus; Johannessen, Hans Olaf; Alexandersson von Döbeln, von; Hjortland, Geir Olav; Wang, N.; Shang, Y.; Borg, D.; Quaas, A.; Bartella, I.; Bruns, C.; Schröder, W.; Nilsson, M. (Peer reviewed; Journal article, 2023)
      Background The optimal time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer is unknown and has traditionally been 4-6 weeks in clinical practice. Observational studies have suggested ...